Takeaways: This notice of allowance shores up Anixa’s IP moat around its AMHR2‑targeted ovarian cancer vaccine and aligns Canada with its existing US patent protection. ...
Takeaways: Quaebec’s reimbursement of Vanflyta is a pivotal step toward pan‑Canadian access for a high‑value, biomarker‑targeted AML therapy. Market-wise, public funding acr...
Artificial intelligence has rapidly moved from a buzzword to a core component of modern drug development. From target identification and molecule design to clinical trial optimization, AI promises to ...
For most of modern medicine, the pharmaceutical industry has operated largely within a reactive healthcare model, developing therapies designed to treat diseases after they emerge. Today, however, adv...
Healthcare is undergoing a major cultural and commercial shift as patients become more informed, digitally connected, and actively involved in their care decisions. What was once a largely physician d...
For decades, women’s health remained one of the most underfunded and underserved areas in healthcare despite representing half the global population. Many conditions affecting women received limited r...
For decades, oncology innovation has focused primarily on developing more effective treatments for advanced disease. Today, however, the industry is beginning to shift toward a new frontier: detecting...
Precision medicine is often defined by breakthrough therapies and targeted treatments, but behind many of these advances lies a less visible yet increasingly essential component: companion diagnostics...
The pharmaceutical industry has long occupied a complex position in public perception, celebrated for life saving innovation yet frequently criticized for pricing practices, transparency concerns, and...
Rare diseases were once considered commercially unattractive due to their limited patient populations and high development costs. Today, however, they have become one of the fastest growing areas of i...
